专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明公开

EP0017477A1 Spiro-quinolone hydantoins, pharmaceutical compositions containing them, and processes for their preparation 有权
标题翻译：螺 - 乙内酰脲喹诺酮类，含有它们的它们的制备方法的药物组合物。
公开(公告)号：EP0017477A1
公开(公告)日：1980-10-15
申请号：EP80301046.1
申请日：1980-04-02
申请人： PFIZER INC.
发明人： Schnur, Rodney Caughren
IPC分类号： C07D471/20 , A61K31/47 , A61K31/55
CPC分类号： C07D215/227 , C07D455/04
摘要： Spiro-quinolone hydantoins having utility in preventing or alleviating chronic diabetic complications such as cataracts, reinopathy and neuropathy of the formula:
and the pharmaceutically acceptable acid addition salts thereof, wherein n is 1 or 2 and R, and R 2 are each hydrogen, chloro, bromo, fluoro, C,-C 3 alkyl or C 1 -C 3 alkoxy; pharmaceutical composition containing them, and processes for their preparation.
摘要翻译：具有螺 - 喹诺酮乙内酰脲效用在预防或减轻慢性糖尿病并发症：如白内障，reinopathy和下式的神经病：... ...和药学上可接受的酸加成盐，worin n是1或2，并且R 1和R 2各自氢，氯，溴，氟，C1-C3烷基或C1-C3烷氧基; 药物组合物含有它们，并且它们的制备方法。

12. 发明授权

EP0117035B1 Aldose reductase inhibiting 5-(2-alkoxyphenyl)thiazolidinediones 有权
标题翻译：降糖抑制5-（2-烷氧基苯基）噻唑烷二酮
公开(公告)号：EP0117035B1
公开(公告)日：1989-08-16
申请号：EP84300155.3
申请日：1984-01-11
申请人： PFIZER INC.
发明人： Schnur, Rodney Caughren
IPC分类号： C07D277/34 , A61K31/425
CPC分类号： C07C255/00 , C07C43/225 , C07C45/513 , C07C59/64 , C07D277/34 , C07C47/575

13. 发明授权

EP0030861B1 Isoquinoline acetic acids and pharmaceutical compositions thereof 有权
标题翻译：异喹啉酸及其药物组合物
公开(公告)号：EP0030861B1
公开(公告)日：1983-07-27
申请号：EP80304517.8
申请日：1980-12-15
申请人： PFIZER INC.
发明人： Schnur, Rodney Caughren
IPC分类号： C07D217/24 , C07D217/22 , A61K31/47
CPC分类号： C07C59/86 , C07D217/22 , C07D217/24

14. 发明授权

EP0034063B1 Hydantoin amines and pharmaceutical compositions thereof 有权
标题翻译： HYDANTOIN AMINES和药物组合物
公开(公告)号：EP0034063B1
公开(公告)日：1983-06-22
申请号：EP81300521.2
申请日：1981-02-09
申请人： PFIZER INC.
发明人： Sarges, Reinhard , Schnur, Rodney Caughren
IPC分类号： C07D491/107 , C07D495/10 , C07D471/10 , A61K31/415 , A61K31/47
CPC分类号： C07D471/10 , C07D491/10 , C07D495/10 , Y10S514/866

15. 发明公开

EP0034063A1 Hydantoin amines and pharmaceutical compositions thereof 有权
标题翻译： Hydantoinamine和它们的药物组合物。
公开(公告)号：EP0034063A1
公开(公告)日：1981-08-19
申请号：EP81300521.2
申请日：1981-02-09
申请人： PFIZER INC.
发明人： Sarges, Reinhard , Schnur, Rodney Caughren
IPC分类号： C07D491/107 , C07D495/10 , C07D471/10 , A61K31/415 , A61K31/47
CPC分类号： C07D471/10 , C07D491/10 , C07D495/10 , Y10S514/866
摘要： A series of amino- and alkylamino-substituted spirohydantoins of the formula:
and the pharmaceutically acceptable salts thereof; wherein X is oxygen, sulfur or N-R, wherein R is hydrogen or alkyl of 1 to 3 carbon atoms;
R 1 is chloro, bromo, fluoro or alkyl of 1 to 3 carbon atoms; one of R 2 and R 3 is hydrogen; and the other of R 2 and R 3 is amino, monoalkylamino or dialkylamino, wherein each alkyl group has from 1 to 3 carbon atoms, and pharmaceutically acceptable salts thereof, useful as inhibitors of the enzyme aldose reductase and as therapeutic agents for the treatment of chronic complications associated with diabetes are disclosed. Preferred compounds include 6-chloro-8-amino-spiro[4H-2,3-dihydro-1-benzopyran-4,4'-imidazolidine]-2',5'-dione, the 6-fluoro and 8-methylamino- analogs thereof and the corresponding dihydroben- zothiopyran analogs of these compounds. The optical isomers of these compounds having the 4S-configuration are especially preferred.

16. 发明公开

EP0014079A1 Spiro-quinolylhydantoins, process for their preparation and pharmaceutical compositions thereof 有权
标题翻译：螺Chinolylhydantoine，它们的制备方法和它们的药物组合物。
公开(公告)号：EP0014079A1
公开(公告)日：1980-08-06
申请号：EP80300170.0
申请日：1980-01-18
申请人： PFIZER INC.
发明人： Schnur, Rodney Caughren
IPC分类号： C07D491/20 , C07D495/20 , A61K31/395
CPC分类号： C07D491/04 , A61K31/47 , C07D215/20 , C07D215/26 , C07D491/20 , C07D495/20
摘要： Novel spiro-qutnolylhydantoin derivatives of the formula:
and the base salts thereof with pharmaceutically acceptable cations, wherein X is oxygen or sulfur; n is zero, one or two;

R is hydrogen, alkyl of 1 to 4 carbon atoms or benzyl; and R,, R 2 and R 3 are each hydrogen, chloro, bromo, fluoro, alkyl of 1 to 3 carbon atoms or phenyl, are useful as aldose reductase inhibitors and as therapeutic agents for the treatment of chronic diabetic complications.

Preferred compounds include spiro[imidazolidin-4,4'--pyrano(3,2-h)quinolin]-2,5-dione and spiro[imidazolidin--4,4'-pyrano(2,3-f)quinolin]-2,5-dione.

17. 发明授权

EP0173497B1 Tetracyclic spiro-hydantoin aldose reductase inhibitors 有权
标题翻译：四氢呋喃 - 丹皮酚降低抑制剂
公开(公告)号：EP0173497B1
公开(公告)日：1989-09-06
申请号：EP85305636.4
申请日：1985-08-08
申请人： PFIZER INC.
发明人： Schnur, Rodney Caughren
IPC分类号： C07D471/20 , A61K31/495
CPC分类号： C07D471/10 , C07C51/16 , C07C59/185 , C07C59/88 , C07D213/55 , C07C59/58

18. 发明公开

EP0091193A3 Antidiabetic compositions 有权
标题翻译：抗菌成分
公开(公告)号：EP0091193A3
公开(公告)日：1984-07-11
申请号：EP83301044
申请日：1983-02-28
申请人： PFIZER INC.
发明人： Morville, Malcolm , Page, Michael Garth , Schnur, Rodney Caughren
IPC分类号： A61K31/64 , A61K31/44 , A61K31/42
CPC分类号： A61K31/64 , A61K31/42 , A61K31/44 , A61K2300/00
摘要： Certain novel oral antidiabetic compositions are disclosed. These pharmaceutical compositions involve the concomitant use of two different organic chemical compounds each chosen from a separate class of known hypoglycemic agents. One class of agents involves certain known oxazolidine-2,4-dione compounds (A), while the other class is primarily concerned with a series of known hypoglycemic sulfonylureas (B). Preferred embodiments involve the use of 5-(3-thienyl)oxazolidine-2,4-dione, 5-(4-ethoxy-3-thienyl)oxazolidine-2,4-dione, 5-(2-methoxy-6-fluorophenyl)oxazolidine-2,4-dione, 5-(2-methoxy-6-chlorophenyl)oxazolidine-2,4-dione or 5-(2-ethoxy-5-chloro-3-pyridyl)oxazolidine-2,4-dione as compound (A) in conjunction with either chlorpropamide or glipizide as compound (B). Various methods for administering these compounds in combination and/or in a concomitant manner are provided.

19. 发明公开

EP0091193A2 Antidiabetic compositions 有权
标题翻译：糖尿病Zusammensetzungen。
公开(公告)号：EP0091193A2
公开(公告)日：1983-10-12
申请号：EP83301044.0
申请日：1983-02-28
申请人： PFIZER INC.
发明人： Morville, Malcolm , Page, Michael Garth , Schnur, Rodney Caughren
IPC分类号： A61K31/64 , A61K31/44 , A61K31/42
CPC分类号： A61K31/64 , A61K31/42 , A61K31/44 , A61K2300/00
摘要： Certain novel oral antidiabetic compositions are disclosed. These pharmaceutical compositions involve the concomitant use of two different organic chemical compounds each chosen from a separate class of known hypoglycemic agents. One class of agents involves certain known oxazolidine-2,4-dione compounds (A), while the other class is primarily concerned with a series of known hypoglycemic sulfonylureas (B). Preferred embodiments involve the use of 5-(3-thienyl)oxazolidine-2,4-dione, 5-(4-ethoxy-3-thienyl)oxazolidine-2,4-dione, 5-(2-methoxy-6-fluorophenyl)oxazolidine-2,4-dione, 5-(2-methoxy-6-chlorophenyl)oxazolidine-2,4-dione or 5-(2-ethoxy-5-chloro-3-pyridyl)oxazolidine-2,4-dione as compound (A) in conjunction with either chlorpropamide or glipizide as compound (B). Various methods for administering these compounds in combination and/or in a concomitant manner are provided.
摘要翻译：公开了某些新颖的口服抗糖尿病组合物。这些药物组合物包括伴随使用两种不同的有机化合物，其各自选自单独的一类已知的降血糖剂。一类试剂涉及某些已知的恶唑烷-2,4-二酮化合物（A），而另一类则主要涉及一系列已知的降血糖磺酰脲类（B）。优选的实施方案包括使用5-（3-噻吩基）恶唑烷-2,4-二酮，5-（4-乙氧基-3-噻吩基）恶唑烷-2,4-二酮，5-（2-甲氧基-6-氟苯基）恶唑烷-2,4-二酮，5-（2-甲氧基-6-氯苯基）恶唑烷-2,4-二酮或5-（2-乙氧基-5-氯-3-吡啶基）恶唑烷-2,4-二酮作为化合物（A）与氯丙酰胺或格列吡嗪一起作为化合物（B）。提供了组合和/或以同时方式施用这些化合物的各种方法。

20. 发明授权

EP0017477B1 Spiro-quinolone hydantoins, pharmaceutical compositions containing them, and processes for their preparation 有权
标题翻译： SPIRO-QUINOLONE HYDANTOINS，含有它们的药物组合物及其制备方法
公开(公告)号：EP0017477B1
公开(公告)日：1982-01-06
申请号：EP80301046.1
申请日：1980-04-02
申请人： PFIZER INC.
发明人： Schnur, Rodney Caughren
IPC分类号： C07D471/20 , A61K31/47 , A61K31/55
CPC分类号： C07D215/227 , C07D455/04

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式